ETS1 and colonic neoplasm: These results indicate β6-integrin might be a novel therapeutic target in colon cancer therapy, and it reminded us that if positive αvβ6 and Ets-1 were found in patients with colon cancer of early stage, compared with negative, we would take more aggressive chemotherapy, or more frequent reexamination.